Organs-on-chips Market Trends

Organs-on-chips Market Trends

The rising prevalence of chronic diseases has led to an increased need for rapid drug discovery methods, growing the necessity for drug toxicity identification, technological progress, and the introduction of new products by major market players. For example, the COVID-19 pandemic had positively influenced the market in investigating the lung’s pathophysiology in patients. For instance, Emulate Inc.'s alveolus lung-chip and airway lung-chip models, played a crucial role in COVID-19 research. These innovative organ-on-chip technology supported in enhancing the early infectious disease clinical studies expediting the pandemic research efforts.
 

• In February 2023, CN Bio introduced the PhysioMimix single-organ higher throughput (HT) system, overcoming the adoption barriers in drug discovery workflows. The launch aimed to expand the drug discovery service capabilities, facilitating larger-scale studies for lead candidate drugs.
   
• Additionally, the growing advancement and the support by the regulatory authorities aimed in accelerating the development and adoption of the advanced organ-on-chip technologies. For instance, FDA Modernization Act 2.0 approval in January 2023 aimed to accelerate the organ-on-chip integration in pharmaceuticals, utilizing innovations in testing methods for ethical and streamlined drug development. The advanced technology provided an opportunity for the pharmaceutical industry to expedite drug development, reducing reliance on animal studies.
   
• Thus, these innovations in organ-on-chip technology hold immense promise for drug development, personalized medicine, and understanding complex biological processes, offering a more ethical and efficient alternative to traditional animal testing. Therefore, the convergence of the aforementioned drivers highlighted the increasing demand for organ-on-chip technology in the coming years.
   

However, a significant challenge for market is the intricate task of reproducing comprehensive organ functionalities, establishing standardized protocols, and obtaining regulatory acceptance. These challenges represent significant constraints impeding the growth of the market.